NEWS R E L E A S E

Ocumetics Achieves Clinical Milestones; Poised for Value-Defining First-in-Human Lens Implantations

For Immediate Release

Calgary, Alberta – August 12, 2025 - Ocumetics Technology Corp. ("Ocumetics" or the "Company") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the successful completion of key clinical milestones and to share an update on the anticipated first-in-human ("FIH") surgeries.

"This is a moment our entire team has been working toward for years," said Dean Burns, CEO of Ocumetics. "Every milestone we've achieved in recent weeks reflects the dedication, expertise, and sheer determination of our people and partners. We're now just a few days away from transforming the future of vision correction with the first implantation of our groundbreaking accommodating intraocular lens. I couldn't be prouder of what our team has accomplished."

Over the past several weeks, Ocumetics has made significant clinical progress:

- June 26, 2025 - Virtual site initiation of the clinical partner site in Mexico City completed, confirming readiness to conduct the FIH clinical study.
- July 9, 2025 - Completion of clinical study protocol training for the clinical team in Mexico City.
- July 30, 2025 - Receipt of verbal ethics committee approval for the study protocol, validating the site's compliance with the highest international standards for patient safety, scientific integrity, and ethical principles.
- August 5, 2025 - Commencement of patient recruitment at the Mexico City clinical site.
- August 8, 2025 - Implantation of control lenses completed.

Upcoming clinical activities include:

- Final site initiation and surgeon training immediately prior to the FIH lens implantations
- First-in-human implantation of the Ocumetics accommodating intraocular lens
- Daily, weekly, and monthly patient progress monitoring
- Planning for Group 2 surgeries, anticipated in Q1 2026

Given the imminent FIH surgeries, the Company has elected not to proceed with the second tranche of the private placement announced on June 4, 2025. Ocumetics successfully completed tranche 1 of the financing, raising $1,124,362 through the issuance of 3,212,462 units. The Company paid fees of $68,610 and issued 196,029 agent's warrants to Numus Capital Corp. for its assistance on the financing. The

Company intends to introduce a financing with revised terms following the completion of these historic procedures.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns	Roger Jewett
President and Chief Executive Officer	Chief Financial Officer
(817) 874-7564	roger.jewett@ocumetics.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.